New drug combo shows promise for Hard-to-Treat bladder cancer
NCT ID NCT03744793
First seen Jan 10, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tested a combination of two drugs, pemetrexed and avelumab, in 18 people with a rare, advanced form of bladder cancer that lacks a protein called MTAP. The goal was to see if the drugs could shrink or control the cancer. Pemetrexed blocks enzymes that cancer cells need to grow, while avelumab helps the immune system attack the cancer. The study is no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.